Marked improvement in gastric involvement in Behçet's disease with adalimumab treatment.

نویسندگان

  • Akira Sonoda
  • Ryo Ogawa
  • Kazuhiro Mizukami
  • Kensuke Fukuda
  • Mitsutaka Shuto
  • Kazuhisa Okamoto
  • Osamu Matsunari
  • Tadayoshi Okimoto
  • Kazunari Murakami
چکیده

Gastric involvement is the least frequent manifestation of Behçet's disease, and effective treatment for it unknown. Here the case of a patient with gastric involvement in Behçet's disease that was markedly improved with adalimumab therapy is presented. A 68-year-old man developed an oral ulcer, erythema, folliculitis, and arthralgia. Behçet's disease was suspected; then, prednisolone and colchicine were administered. Esophagogastroduodenoscopy showed a punched-out ulcer in the posterior wall of the gastric antrum. Ileocolonoscopy showed multiple punched-out ulcers in the terminal ileum. Capsule endoscopy showed multiple circular ulcers throughout the entire small intestine. A diagnosis of non-steroidal, anti-inflammatory, drug-induced enteritis was made. Withdrawal from diclofenac and initiation of lansoprazole healed the circular ulcers in the small intestine, but were ineffective for the gastric ulcer and punched-out ulcers in the terminal ileum. Eradication of Helicobacter pylori was also ineffective. A diagnosis of gastric involvement of Behçet's disease was then made, and the gastric ulcer became steroid-dependent. Mesalazine powder was ineffective, and the patient was intolerant to azathioprine. Adalimumab healed the gastric ulcer, and prednisolone was withdrawn. The outcome of the present patient suggests that adalimumab is effective in the treatment of gastric involvement in Behçet's disease.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Long-term safety and efficacy of adalimumab for intestinal Behçet's disease in the open label study following a phase 3 clinical trial

BACKGROUND/AIMS Intestinal Behçet's disease (BD) is an immune-mediated inflammatory disorder. We followed up the patients and evaluated safety profile and effectiveness of adalimumab for the treatment of intestinal BD through 100 weeks rolled over from the 52 week clinical trial (NCT01243671). METHODS Patients initiated adalimumab therapy at 160 mg at week 0, followed by 80 mg at week 2, foll...

متن کامل

Efficacy of adalimumab in patients with Behçet's disease unsuccessfully treated with infliximab.

OBJECTIVES To evaluate the clinical response after switching from infliximab to adalimumab in patients with Behçet's disease (BD). METHODS In this ongoing, prospective, longitudinal and observational study, data were collected on efficacy and safety of every patient with BD beginning anti-TNF therapy in the last 8 years. The present analysis was restricted to patients who were switched to ada...

متن کامل

The real-world use of different anti-tumor necrosis factor agents in a Northern European population of patients with Behçet's disease.

Objective The aim of this study was to evaluate prescription practices, treatment responses, and serious adverse events of anti-tumor necrosis factor (anti-TNF) therapies in Behçet's disease (BD). Material and Methods Patients with BD satisfying the International Study Group for Behçet's Disease or the International Criteria for Behçet's Disease criteria were recruited from a regional rheumat...

متن کامل

[Efficacy of adalimumab in Behçet's disease. Description of 6 cases].

Behçet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab. We observed a good clinical response in all patients. To date, after a mean...

متن کامل

Superior efficacy of Adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: Adalimumab as starting anti-TNF-α therapy in childhood chronic uveitis

BACKGROUND Nonetheless biologic modifier therapies are available treatment strategies for sight-threatening uveitis in children, the lack of evidence from head-to-head randomized controlled studies limits our understanding of timing of therapy when to commence therapy, which agent to choose and how long to continue treatment, and, in case of failure, if switching to another anti-TNF-α strategy ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology

دوره 28 5  شماره 

صفحات  -

تاریخ انتشار 2017